However, the company’s revenue from operations declined to Rs 782 crore, compared with Rs 818 crore in the year-ago quarter, Wockhardt said in a statement.
The company’s India business contributed Rs 172 crore during the quarter, reflecting a 3 per cent growth compared to the previous year, it added. The UK business generated Rs 313 crore, a growth of 4 per cent compared to the previous year, PTI reported.
Besides, the Ireland business stood at Rs 59 crore in the second quarter with a growth of 40 per cent compared to the previous year, it added.
"We see significant scale up and advancing our leadership in the Biotech diabetes segment on the back of new partnerships in the Emerging markets and India, entry into new markets like Russia and Malaysia as we commit to offer affordable Insulin globally,” it said.
Read also: Wockhardt seeks USFDA approval for Zidebactam-Cefepime injection to treat Serious GramNegative Infections
Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt’s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt has USFDA's QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”
. It has manufacturing and research facilities in India and UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in Europe and India, with 79% of its global revenues coming from international businesses.Read also: CDSCO Panel Asks Wockhardt to Revise Phase III Study Protocol for Nafithromycin, Seeks Dosing, Control Arm Changes
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.